Compare Abbott Laboratories (ABT) vs KLA Corp. (KLAC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs KLA Corp. — how do they compare? Abbott Laboratories trades at $95.25 (market cap $166.94B), while KLA Corp. trades at $220.95 (market cap $282.77B). The key difference: KLA Corp. is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | KLAC | |
|---|---|---|
Market Cap | $166.94B | $282.77B |
Sector | Health | Technology |
52-Week High | $136.62 | $301.71 |
52-Week Low | $82.57 | $84.39 |
Enterprise Value | $193.69B | $283.96B |
Dividend Yield | 2.63% | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
KLA Corporation (KLAC) trades at $216.47, down 8.1% over 24 hours, amid a broader semiconductor selloff. The stock maintains strong fundamentals with a 35.66% net income margin and consistent earnings beats, including Q1 2026 EPS of $0.94 versus $0.917 expected. A 1:10 stock split is scheduled for June 12, 2026, and the company pays a $2.30 dividend. Technical indicators show a bearish short-term trend with support near $209.
KLAC's outlook is supported by robust profitability and AI-driven demand, but high valuation ratios (P/E 66.07) pose risks. Analyst consensus is bullish with a $228.42 price target, though sector volatility and competitive pressures require monitoring. The stock offers growth potential tempered by market sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
